Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract. Although OTC treatment for OIC is common…
This folder covers DRG’s Company & Drugs (C&D) data for Transplants which include market forecast (US, ROW and Global) and analysis on drug profie, drug group and therapy area.
The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which…
Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. There have been significant…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Because no current therapy for type 2 diabetes offers disease-modifying capabilities, a high unmet need exists for drugs that can effectively control the progression of this prevalent disease…
MARKET OUTLOOK Treatment for PsA typically begins with a cDMARD, but often progresses to a tsDMARD or bDMARD within two years. TNFi are the mainstay of treatment for recently treated…
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…
Due to rising antimicrobial resistance (AMR) rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs…
Hepatitis C virus (HCV) affects thousands of individuals in Mexico and Argentina. The launch of innovative therapies in recent years has brought new, highly effective options to the market, but…
The hepatitis C virus (HCV) therapy market has been marked by tremendous growth, and the treatment landscape has undergone a rapid evolution with the launch of novel direct-acting antivirals (DAAs…
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine…
Abstract: Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (…